Matinas BioPharma August 2024 Corporate Presentation

Matinas BioPharma's presentation outlines its lipid nanocrystal (LNC) delivery platform designed to enhance therapeutic value across oncology and inflammation. The company highlights its Phase 3-ready ORALTO candidate for invasive aspergillosis treatment and discusses LNC capabilities for improved oral delivery, reduced toxicity, and expanded cargo potential including small molecules and oligonucleotides.